申请人:Polaris Pharmaceuticals, Inc.
公开号:US20180065917A1
公开(公告)日:2018-03-08
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.
For Formula (I) compounds R
1
, R
2
, X
1
, Y
1
and n are as defined in the specification. The inventive Formula (I) compounds are inhibitors of the PD-1/PD-L1 protein/protein binding or functional interaction and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer and infectious diseases.
本发明提供了根据式(I)的化合物的合成、药学上可接受的制剂及其用途,或其立体异构体、互变异构体或药学上可接受的盐。对于式(I)化合物,R1、R2、X1、Y1和n如说明书中所定义。本发明的式(I)化合物是PD-1/PD-L1蛋白/蛋白结合或功能性相互作用的抑制剂,并可用于多种治疗应用,包括但不限于治疗增殖性疾病,如癌症和传染病。